Scholarlink

<p>The diagnostic delay in celiac disease (CD) is currently a burden for individual and society. Biochemical tests may be used in risk-identification of CD to reduce the diagnostic delay, and we aimed to explore prediction models for CD antibody seropositivity. We developed two prediction models in a cohort study using data from primary care in greater Copenhagen (2006–2015). All patients with CD antibody tests were included. Two candidate sets of predictors were considered: (1) all blood tests measured, (2) tests deemed clinically relevant pre-study or previously studied. Both models assessed test results 5 years before CD-testing. We developed and evaluated prediction models in 10-fold cross-validation framework for each set of predictors. Four machine learning methods were combined in stacked models using SuperLearner. 54,877 patients were included, 672 CD antibody seropositive. Cross-validated estimated area under the curves were 0.68 and 0.63. Distributions of predicted probabilities overlapped substantially between patients with CD antibody seropositivity and seronegativity. Food allergen antibody and IgA were the most important predictors. Biochemical tests had low predictive power but provided methodological insights for future models. These may improve by combining biochemical tests with other clinical information but should preferably aim to stay clinically implementable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Machine learning-based prediction of celiac antibody seropositivity by biochemical test parameters

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月3日

查看全文
  • Signe Ulfbeck Schovsbo,
  • Michael Charles Sachs,
  • Margit Kriegbaum,
  • Anne Ahrendt Bjerregaard,
  • Line Tang Møllehave,
  • Susanne Hansen,
  • Bent Struer Lind,
  • Tora Grauers Willadsen,
  • Allan Linneberg,
  • Christen Lykkegaard Andersen,
  • Line Lund Kårhus

摘要

The diagnostic delay in celiac disease (CD) is currently a burden for individual and society. Biochemical tests may be used in risk-identification of CD to reduce the diagnostic delay, and we aimed to explore prediction models for CD antibody seropositivity. We developed two prediction models in a cohort study using data from primary care in greater Copenhagen (2006–2015). All patients with CD antibody tests were included. Two candidate sets of predictors were considered: (1) all blood tests measured, (2) tests deemed clinically relevant pre-study or previously studied. Both models assessed test results 5 years before CD-testing. We developed and evaluated prediction models in 10-fold cross-validation framework for each set of predictors. Four machine learning methods were combined in stacked models using SuperLearner. 54,877 patients were included, 672 CD antibody seropositive. Cross-validated estimated area under the curves were 0.68 and 0.63. Distributions of predicted probabilities overlapped substantially between patients with CD antibody seropositivity and seronegativity. Food allergen antibody and IgA were the most important predictors. Biochemical tests had low predictive power but provided methodological insights for future models. These may improve by combining biochemical tests with other clinical information but should preferably aim to stay clinically implementable.